The TESEO registry and how it can help patients with CAT
Cancer-associated thrombosis management is incredibly challenging because of the high risk of recurrence and severe...
Trials and Therapy
Inpatient thromboprophylaxis in cancer patients: what is the evidence? A talk report from the 10th ICTHIC
During the 10th ICTHIC, Prof. Jeffrey Zwicker (Harvard Medical School, MA, USA) gave an overview of the evidence of the...
Awareness of venous thromboembolism risk in cancer patients: the oncologist knowledge gap
The management of cancer-associated venous thrombosis (CAT) is particularly challenging because of a high risk of major...
Is apixaban safe for primary VTE prevention in patients with gastrointestinal cancers? A summary of a post-hoc analysis of the AVERT trial
Patients with cancer and a Khorana score ≥2 have an estimated risk of symptomatic venous thromboembolism (VTE) of...
Investigating the drug−drug interactions occurring in cancer-associated thrombosis: use of checkpoint inhibitors and direct oral anticoagulants in a real-world setting
Advances in medicine and the possibility of keeping multiple diseases under control via medication have increased the...
The USCAT study: a retrospective non-interventional study to examine long-term treatment of CAT
Patients with cancer are at high risk of venous thromboembolism (VTE) recurrence and major bleeding (1). Most...
The Art of Managing Cancer-Associated Thrombosis: Caravaggio and Beyond
Venous thromboembolism (VTE) is a frequent complication and the second leading cause of death in cancer patients....
Toward the replacement of low-molecular-weight heparins with the novel direct oral anticoagulants for the treatment of cancer-associated thrombosis
Value and limitations of low-molecular-weight heparins Following the demonstration that vitamin K antagonists (VKA) are...
Incidental venous thromboembolism in cancer patients
It is well known that patients with cancer are at high risk of venous thromboembolism (VTE), especially when initiating...
Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...